PEG-interferon alfa-2b

ApprovedBiologic

Merck & Co.

PEG-interferon alfa-2b is one of 271 biologic programs targeting Glioma. It is currently in Approved.

Indications

Total Trials

Active Trials

270

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Kidney CancerActive, not recruiting

Metastatic MelanomaActive, not recruiting

Chronic HepatitisActive, not recruiting

Carcinoid TumorActive, not recruiting

Fallopian Tube CancerActive, not recruiting

MelanomaActive, not recruiting

Hepatitis CActive, not recruiting

Adult T-Cell Leukemia/lymphomaActive, not recruiting

GliomaPhase 2

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

Carcinoid TumorPhase 2

Active, not recruiting

Fallopian Tube CancerPhase 1/Phase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Hepatitis CApproved

Active, not recruiting

Adult T-Cell Leukemia/lymphomaApproved

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

PEG-interferon alfa-2b

Merck & Co.

Approved

1 2

Cyklokapron

AAmring

Phase 3

1 3

KIMMTRAK

IImmunocore Ltd

Phase 3

2 4

Pegylated Interferon-Alpha-2a

AstraZeneca

Phase 3

1 5

GSK2118436

GSK

Phase 3

1 6

Interferon-Alpha-2a

Roche

Phase 3

1 7

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 8

High-Dose Recombinant Interferon A-2b

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

1 9

Cancervax Vaccine (CANVAXIN)

CCancerVax Corporation

Phase 3

2 10

Intron a

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Kidney Cancer4 trials

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Terminated·CCalifornia Cancer Consortium·Phase 2·NCT00467077·21 enrolled

PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Terminated·TThomas Olencki·Phase 1·NCT00589550·1 enrolled

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

Terminated·MMedical University of South Carolina·Phase 2·NCT00090870·10 enrolled

Show 1 more trial

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00045279

Hepatitis C2 trials

Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00122629·405 enrolled

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT01443923·4 enrolled

Immunotherapy1 trial

Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults

Enrolling by invitation·—·N/A·NCT06777173·180 enrolled

Carcinoid Tumor1 trial

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00055809·44 enrolled

Adult T-Cell Leukemia/lymphoma1 trial

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

Terminated·UUniversity of Miami·Phase 4·NCT00854581·13 enrolled

10 more indications

Glioma1 trial

Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00047879·7 enrolled

Fallopian Tube Cancer1 trial

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00085384·30 enrolled

Chronic Hepatitis1 trial

Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01353911·368 enrolled

Solid Tumors1 trial

Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03554005·29 enrolled

Chronic1 trial

Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01945294·257 enrolled

Patients With Advanced Solid Tumors1 trial

Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00014261

Melanoma1 trial

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00049530·32 enrolled

Hematological Malignancies1 trial

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Completed·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2/3·NCT02634294·30 enrolled

Head and Neck Cancer1 trial

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00276523·3 enrolled

Metastatic Melanoma1 trial

PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00238329·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for PEG-interferon alfa-2b. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEG-interferon alfa-2b compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEG-interferon alfa-2b. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: Merck & Co.

PEG-interferon alfa-2b

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Kidney Cancer4 trials

Hepatitis C2 trials

Immunotherapy1 trial

Carcinoid Tumor1 trial

Adult T-Cell Leukemia/lymphoma1 trial

Glioma1 trial

Fallopian Tube Cancer1 trial

Chronic Hepatitis1 trial

Solid Tumors1 trial

Chronic1 trial

Patients With Advanced Solid Tumors1 trial

Melanoma1 trial

Hematological Malignancies1 trial

Head and Neck Cancer1 trial

Metastatic Melanoma1 trial

References

Drug Info

Quick Facts

Related News